Navigation Links
DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
Date:6/15/2010

YDUREON produced an average weight loss of 4.5 pounds, which was statistically significantly greater than the average 1.7 pounds patients lost with Januvia and the average 3.3 pounds patients gained with Actos. Patients receiving metformin experienced an average weight loss of 4.4 pounds.

"The majority of patients in this study reached an optimal A1C goal of less than seven percent, which is the glucose control target recommended by the American Diabetes Association," said Orville G. Kolterman, M.D., senior vice president, chief medical officer, Amylin Pharmaceuticals. "DURATION-4 reinforced that continued presence of exenatide helped these recently diagnosed patients to achieve glycemic control. The combination of efficacy, tolerability, and once weekly dosing in this monotherapy setting further supports the potential role BYDUREON can play in helping patients and physicians manage type 2 diabetes."

More than 80 percent of patients in all treatment arms completed the study. There were no major hypoglycemia events in any treatment group. The most frequently reported adverse events among BYDUREON users were nausea (withdrawal rate less than 1 percent) and diarrhea; metformin, diarrhea and headache; Actos, upper respiratory tract infection, headache, hypertension and peripheral edema; and Januvia, upper respiratory tract infection and headache.

BYDUREON (pronounced by-DUR-ee-on) is the proposed brand name for exenatide once weekly. It is an investigational, extended-release medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. BYDUREON is a once-weekly formulation of exenatide, the active ingredient in BYETTA® (exenatide) injection, which has been available in the U.S. since June 2005 and is used in approximately 60 countries worldwide to
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   SurePure, Inc ... photopurification, announced today that the Company has completed ... continued trading of SurePure ("SURP") securities on OTCQB, ... for entrepreneurial and development stage companies. ... standards and eligibility requirements designed to improve marketplace ...
(Date:3/27/2015)... ROCKVILLE, Md. , March 27, 2015  CASI ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a commercial focus on ... the three and 12 months ended December 31, 2014.  ... of ($1.6 million), or ($0.05) per share, for the ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... that after dealing with certain matters, including the appointment ... held on March 26, 2015 (the "Meeting") was adjourned, ... 8, 2015 at 11:00 a.m. ( Toronto ... been changed from that previous disclosed. The Meeting will ...
(Date:3/26/2015)... March 26, 2015 Neogen Corporation (NASDAQ: ... the third quarter of fiscal 2015, which ended Feb. ... prior year,s $6,575,000. Earnings per share in the current ... Current year-to-date net income increased 17% over prior year ... or $0.56 per share, for the same period a ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6SQI Diagnostics Inc. Announces Adjournment of Meeting 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... N.J., March 18 Sopherion Therapeutics, LLC, a ... of anti-cancer therapies, announced that it completed enrollment ... liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. ... of Sopherion,s lead product in combination with the ...
... Troy, N.Y. Researchers at Rensselaer Polytechnic Institute ... copper nanorods, a key step for advancing integrated ... fuse together, or anneal, at about 300 degrees ... the nanorods ideal for use in heat-sensitive nanoelectronics, ...
... PLYMOUTH MEETING, Pa., March 17 /PRNewswire-Asia-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: ... for the fourth quarter and fiscal year ended,December 31, 2008. , ... -- Fourth quarter revenues increased to $36.6 million, ... fourth quarter of 2007., -- Non-GAAP operating income, ...
Cached Biology Technology:Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 2Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 3Slimmer, stickier nanorods give boost to 3-D computer chips 2BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 2BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 3BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 4BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 5BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 6BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 7BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 8BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 9BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 10BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 11BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 12
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... who contract gastroenteritis from drinking water contaminated with ... high blood pressure, kidney problems and heart disease in later ... Medical Journal . The findings underline the importance of ... for regular monitoring for those affected. It is estimated ...
... Physical activity promotes changes in the brain that ... of Alzheimer,s disease, according to a new study done ... Carson Smith, an assistant professor of health sciences, included ... gene for Alzheimer,s disease, and other healthy older adults ...
... Va. Since the Civil War, the stethoscope has been ... average doctor may be toting another valuable diagnostic tool: a ... professor of internal medicine at Eastern Virginia Medical School, believes ... years they will become commonplace," he predicts. Dr. Levitov, ...
Cached Biology News:E coli infection linked to long-term health problems 2Study shows importance of exercise for those at special risk for Alzheimer's 2Author predicts widespread acceptance of pocket-sized ultrasound machines 2
Human FADD Affinity Purified Polyclonal Ab...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
... Ac-DEVD-CHO is an ... activity. The concentration of ... caspase activity must be ... system. Ten micromolar inhibitor ...
Biology Products: